Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE trial
NL-OMON23620Active, not recruiting
- Sponsor
- VU University Medical Center, Amsterdam The Netherlands
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of valsartan and rosiglitazone in impaired fasting glucose (IFG), prediabetes and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by VU University Medical Center, Amsterdam The Netherlands. Primary endpoints: First-phase insulin secretion corrected for insulin sensitivity and Arginine-stimulated insulin secretion. Started Oct 2006; status: active, not recruiting.
02
Drugs
valsartanrosiglitazone
03
Conditions
impaired fasting glucose (IFG)prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON23620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23620.